Stay updated on Niraparib & Pembrolizumab in TNBC & Ovarian Cancer Clinical Trial
Sign up to get notified when there's something new on the Niraparib & Pembrolizumab in TNBC & Ovarian Cancer Clinical Trial page.

Latest updates to the Niraparib & Pembrolizumab in TNBC & Ovarian Cancer Clinical Trial page
- Check6 days agoNo Change Detected
- Check13 days agoChange DetectedFallopian tube cancer was added to the conditions list and Genetic and Rare Diseases Information Center resources were added. The page revision was updated from v3.4.1 to v3.4.2.SummaryDifference0.2%

- Check20 days agoChange DetectedRevision tag updated from v3.4.0 to v3.4.1. No visible changes to the study details were observed.SummaryDifference0.0%

- Check27 days agoChange DetectedAdded a 'Show glossary' option and the 'No FEAR Act Data' text. Updated footer labels to 'Last Update Submitted that Met QC Criteria' and introduced 'Revision: v3.4.0'.SummaryDifference0.2%

- Check42 days agoChange DetectedThe page revision label was updated from v3.3.3 to v3.3.4; there are no substantive changes to study details, eligibility criteria, or navigation. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check63 days agoChange DetectedLocations section added listing participating sites by state (e.g., Alabama, Arizona, California, District of Columbia, Florida, Illinois, Louisiana, Massachusetts, Michigan, Minnesota, New Jersey, New York, North Carolina, Ohio, Oklahoma, Tennessee, Texas, Virginia, Washington). The page revision updated to v3.3.3.SummaryDifference2%

- Check92 days agoChange DetectedA note clarifying that PubMed publications are automatically filled and may not be about the study; revision: v3.3.2.SummaryDifference0.1%

Stay in the know with updates to Niraparib & Pembrolizumab in TNBC & Ovarian Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Niraparib & Pembrolizumab in TNBC & Ovarian Cancer Clinical Trial page.